RxDoctor Payments Data

Staycha Lee, NP

Nurse Practitioner · St George, UTNPI 1346817061

Payments from drug & device makers

$2,262in general payments, 2019–2025

Across 122 payments — averaging $18.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$944
  • Biohaven Pharmaceutical Holding Company Ltd.$235
  • Lilly USA, LLC$139
  • Pfizer$136
  • Biohaven Pharmaceuticals, Inc.$133
  • GSK$89
  • plus $586 from 18 others

What the payments were for

  • Food & beverage$2,262100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,262 in reported general payments places this provider in the 85th percentile of 979 nurse practitioner providers in Utah.

See all nurse practitioner providers in Utah

Medicare billing

Part B allowed, 2024
$77,118
Medicare patients
340
Services billed
4,177

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide56$62,617
JardianceEmpagliflozin62$49,073
EliquisApixaban29$31,559
XareltoRivaroxaban14$22,575
MounjaroTirzepatide13$19,629
Lisdexamfetamine Dimesylate14$2,333
Omeprazole121$2,077
Estradiol26$1,796
Losartan Potassium140$1,786
Atorvastatin Calcium169$1,601
Levothyroxine Sodium161$1,588
Bupropion XlBupropion Hcl77$1,466
Tramadol Hcl60$1,433
Gabapentin81$1,236
Sertraline Hcl57$959

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$13$62,61756 claims
Boehringer IngelheimJardiance$73$49,07362 claims
PfizerEliquis$136$31,55929 claims
Johnson & JohnsonXarelto$82$22,57514 claims
Lilly USA, LLCMounjaro$139$19,62913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 979 nurse practitioner providers in Utah.

Other nurse practitioner in St George

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →